Cisplatin liposomal - Transave
Alternative Names: SLIT cisplatinLatest Information Update: 12 Jan 2022
At a glance
- Originator Transave
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Lung cancer; Non-small cell lung cancer
Most Recent Events
- 19 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
- 12 Oct 2005 Cisplatin is available for licensing (http://www.transaveinc.com)
- 21 Mar 2005 Clinical data from a media release have been added to the adverse events section